Edgestream Partners L.P. Has $1.48 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Edgestream Partners L.P. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 87.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,755 shares of the company’s stock after selling 18,507 shares during the period. Edgestream Partners L.P.’s holdings in IDEXX Laboratories were worth $1,478,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IDXX. Lido Advisors LLC boosted its stake in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Lido Advisors LLC now owns 1,976 shares of the company’s stock worth $1,060,000 after acquiring an additional 22 shares in the last quarter. Schroder Investment Management Group lifted its holdings in IDEXX Laboratories by 295.1% in the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after purchasing an additional 235,863 shares during the last quarter. Mackenzie Financial Corp boosted its position in IDEXX Laboratories by 0.8% during the second quarter. Mackenzie Financial Corp now owns 149,522 shares of the company’s stock worth $80,195,000 after purchasing an additional 1,199 shares during the period. Skandinaviska Enskilda Banken AB publ grew its holdings in IDEXX Laboratories by 42.7% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 23,335 shares of the company’s stock valued at $12,515,000 after purchasing an additional 6,978 shares during the last quarter. Finally, F m Investments LLC grew its holdings in IDEXX Laboratories by 0.5% during the second quarter. F m Investments LLC now owns 27,311 shares of the company’s stock valued at $14,648,000 after purchasing an additional 133 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Down 0.5%

Shares of IDEXX Laboratories stock opened at $714.10 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The firm has a market capitalization of $57.02 billion, a PE ratio of 56.63, a price-to-earnings-growth ratio of 4.28 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The company’s fifty day moving average price is $675.94 and its two-hundred day moving average price is $612.34.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on IDXX shares. UBS Group upped their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. Morgan Stanley lifted their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $730.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.98% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.